{
  "retracted": false,
  "timestamp": 1543622400000,
  "updates": [
    {
      "timestamp": 1585037556763,
      "identifier": {
        "doi": "10.1016/j.neuropharm.2018.10.012"
      },
      "type": "erratum"
    }
  ],
  "identifier": {
    "doi": "10.1016/j.neuropharm.2018.09.025"
  },
  "publisher": "Elsevier BV",
  "title": "Corrigendum to “Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's antiseizure efficacy” [Neuropharmacology 143 (2018) 186–204]"
}
